Peptide medicine group to meet OMB over pending FDA compounding rule
The American Academy of Peptide Medicine is scheduled to meet the Office of Management and Budget Wednesday about a regulation that could widen compounded peptide access.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 19 04:59 ETSource: Semafor
The wire
- 01A regulation under White House review could expand access to peptides; the American Academy of Peptide Medicine is slated to meet with OMB on Wednesday, Semafor reports.
- 02In July an FDA advisory panel, which included individuals with ties to the peptide industry, narrowly recommended adding several peptides to the compounding list over FDA scientists' objections.
- 03Alliance for Pharmacy Compounding CEO Scott Brunner said the notice could be potentially significant but that the policy text, covered peptides and any FDA conditions remain unknown.
From the source
Read at semafor.comPeptide group to meet with White House over pending regulatory plan
A pending regulation under White House review could expand access to peptides, largely unregulated substances that are popular with wellness influencers and Health and Human Services Secretary Robert F. Kennedy Jr.
